MCID: NSL006
MIFTS: 40

Nasal Cavity Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Nasal Cavity Squamous Cell Carcinoma

MalaCards integrated aliases for Nasal Cavity Squamous Cell Carcinoma:

Name: Nasal Cavity Squamous Cell Carcinoma 12 14 69
Squamous Cell Carcinoma of the Nasal Cavity 12
Squamous Cell Carcinoma of Nasal Cavity 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5515
NCIt 47 C8192
UMLS 69 C0280333

Summaries for Nasal Cavity Squamous Cell Carcinoma

Disease Ontology : 12 A nasal cavity carcinoma that has material basis in squamous cells.

MalaCards based summary : Nasal Cavity Squamous Cell Carcinoma, also known as squamous cell carcinoma of the nasal cavity, is related to facial arteriovenous malformation and familial short qt syndrome, and has symptoms including pain and rhinorrhea. An important gene associated with Nasal Cavity Squamous Cell Carcinoma is MMP2 (Matrix Metallopeptidase 2), and among its related pathways/superpathways are Degradation of the extracellular matrix and Interleukin-4 and 13 signaling. The drugs Tegafur and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and growth/size/body region

Related Diseases for Nasal Cavity Squamous Cell Carcinoma

Diseases related to Nasal Cavity Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 facial arteriovenous malformation 10.9 MMP2 MMP9
2 familial short qt syndrome 10.8 MMP2 MMP9
3 kleptomania 10.8 MMP2 MMP9
4 acquired hemangioma 10.8 MMP2 MMP9
5 transitional meningioma 10.8 MMP2 MMP9
6 drug rash with eosinophilia and systemic symptoms 10.8 MMP2 MMP9
7 tinea profunda 10.8 MMP2 MMP9
8 xanthogranulomatous cholecystitis 10.8 MMP2 MMP9
9 collagenous colitis 10.8 MMP2 MMP9
10 sialadenitis 10.8 MMP2 MMP9
11 corneal staphyloma 10.8 MMP2 MMP9
12 limbic encephalitis 10.7 MMP2 MMP9
13 childhood endodermal sinus tumor 10.7 MMP9 TIMP2
14 common variable immunodeficiency 10.7 MMP9 TIMP1
15 nasal cavity adenocarcinoma 10.7 MMP2 MMP9
16 congenital hemolytic anemia 10.7 KRT5 KRT8
17 immunodeficiency 27b, mycobacteriosis, ad 10.6 MMP9 TIMP1
18 tuberculous salpingitis 10.6 MMP9 TIMP1
19 olivopontocerebellar atrophy deafness 10.6 KRT5 KRT8
20 influenza 10.5 MMP2 MMP9
21 clear cell squamous cell skin carcinoma 10.5 KRT7 MMP9
22 adenosine monophosphate deaminase 1 deficiency 10.5 MMP2 MMP9 TIMP2
23 anal squamous cell carcinoma 10.5 CDKN2A KRT5
24 prostaglandin-endoperoxide synthase deficiency 10.5 KRT7 KRT8
25 urethra clear cell adenocarcinoma 10.5 KRT5 KRT8
26 engraftment syndrome 10.5 KRT7 KRT8
27 cervical adenosquamous carcinoma 10.5 CDKN2A KRT5
28 trachea adenoid cystic carcinoma 10.5 KRT7 KRT8
29 lung papillary adenocarcinoma 10.5 MMP2 MMP9 TIMP1
30 lipid-cell variant infiltrating bladder urothelial carcinoma 10.5 KRT5 KRT7
31 mucoepidermoid esophageal carcinoma 10.5 KRT5 KRT7
32 vulva fibroepithelial polyp 10.5 MMP2 MMP9 TIMP1
33 spinal cord intramedullary teratoma 10.5 MMP2 MMP9 TIMP1
34 cribriform carcinoma 10.5 KRT5 KRT8
35 childhood spinal cord tumor 10.5 ANKRD11 KRT5
36 spindle cell liposarcoma 10.5 CDKN2A KRT8
37 female breast axillary tail cancer 10.4 KRT5 KRT7
38 benign dermal neurilemmoma 10.4 CDKN2A KRT5
39 lobular neoplasia 10.4 KRT5 KRT7
40 gait apraxia 10.4 MMP2 TIMP1 TIMP2
41 hodgkin's lymphoma, mixed cellularity 10.4 CDKN2A MMP2 MMP9
42 atrophic gastritis 10.4 CDKN2A MMP2 MMP9
43 congenital methemoglobinemia 10.4 MMP2 TIMP1
44 trachea squamous cell carcinoma 10.4 CDKN2A MMP2 MMP9
45 orbital lymphangioma 10.4 CDKN2A MMP2 MMP9
46 bardet-biedl syndrome 10.4 CDKN2A MMP2 MMP9
47 pulmonary sarcoidosis 10.4 MMP9 TIMP1 TIMP2
48 accommodative esotropia 10.4 MMP2 TIMP1 TIMP2
49 villous adenoma 10.4 CDKN2A MMP2 MMP9
50 small cell cancer of the lung, somatic 10.3 CDKN2A MMP2 MMP9

Graphical network of the top 20 diseases related to Nasal Cavity Squamous Cell Carcinoma:



Diseases related to Nasal Cavity Squamous Cell Carcinoma

Symptoms & Phenotypes for Nasal Cavity Squamous Cell Carcinoma

UMLS symptoms related to Nasal Cavity Squamous Cell Carcinoma:


pain, rhinorrhea

GenomeRNAi Phenotypes related to Nasal Cavity Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.44 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.44 KRT5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.44 KRT5 KRT8
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.44 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.44 KRT8
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.44 KRT7
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.44 KRT5 KRT7 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.44 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.44 KRT5 KRT7

MGI Mouse Phenotypes related to Nasal Cavity Squamous Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.28 ANKRD11 CDKN2A FRS2 KRT5 KRT8 MMP2

Drugs & Therapeutics for Nasal Cavity Squamous Cell Carcinoma

Drugs for Nasal Cavity Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tegafur Approved Phase 3 17902-23-7 5386
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
4
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
5 Racepinephrine Approved Phase 3,Phase 2
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
7
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Fluorouracil Approved Phase 2, Phase 3, Phase 1 51-21-8 3385
10
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
Doxepin Approved Phase 3 1668-19-5 667477 667468
12
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
15
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
17
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
18
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2 216974-75-3
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
23 Antimetabolites Phase 3,Phase 1,Phase 2
24 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
25
s 1 (combination) Phase 3
26 Adrenergic Agents Phase 3,Phase 2
27 Adrenergic Agonists Phase 3,Phase 2
28 Adrenergic alpha-Agonists Phase 3,Phase 2
29 Adrenergic beta-Agonists Phase 3,Phase 2
30 Anti-Asthmatic Agents Phase 3,Phase 2
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
33 Autonomic Agents Phase 3,Phase 2
34 Bronchodilator Agents Phase 3,Phase 2
35 Epinephryl borate Phase 3,Phase 2
36 Mydriatics Phase 3,Phase 2
37 Neurotransmitter Agents Phase 3,Phase 2
38 Peripheral Nervous System Agents Phase 3,Phase 2
39 Respiratory System Agents Phase 3,Phase 2
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
41 Vasoconstrictor Agents Phase 3,Phase 2
42 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
43 Antimitotic Agents Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
45 Antirheumatic Agents Phase 3,Phase 2
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
48 Liver Extracts Phase 3,Phase 2,Phase 1
49 Anti-Infective Agents Phase 2, Phase 3,Phase 1
50 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 183)

id Name Status NCT ID Phase Drugs
1 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
2 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
3 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
4 Laryngeal Preservation in Pyriform Sinus Carcinoma Completed NCT00770393 Phase 2, Phase 3
5 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
6 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
7 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
8 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
9 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
10 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
13 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
14 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
15 Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial Recruiting NCT02765503 Phase 3
16 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
17 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
18 Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12) Unknown status NCT01220752 Phase 2
19 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
20 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00833261 Phase 2 cetuximab;cisplatin
21 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
22 Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003257 Phase 2
23 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
24 Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy Unknown status NCT00004226 Phase 1, Phase 2
25 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
26 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
27 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
28 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
29 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
30 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
31 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
32 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
33 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
34 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
35 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00387335 Phase 2 sunitinib malate
36 Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00098631 Phase 2 lapatinib ditosylate
37 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
38 Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer Completed NCT00004070 Phase 1, Phase 2
39 Randomized Amifostine For SCCHN Completed NCT00095927 Phase 2 Amifostine;Carboplatin;Paclitaxel
40 Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer Completed NCT00006033 Phase 2 methotrexate
41 ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck Completed NCT00015964 Phase 2 ZD1839
42 SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck Completed NCT00006361 Phase 2 semaxanib
43 Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00006471 Phase 2 Fenretinide
44 Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00003850 Phase 2 thalidomide
45 Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002922 Phase 2 paclitaxel
46 S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00337129 Phase 2 eribulin mesylate
47 BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00057850 Phase 1, Phase 2 cisplatin;ixabepilone
48 Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer Completed NCT00503997 Phase 2 oxaliplatin;pemetrexed disodium
49 Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer Completed NCT00248560 Phase 2 docetaxel;gemcitabine hydrochloride
50 S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00006248 Phase 2 cisplatin;fluorouracil;paclitaxel

Search NIH Clinical Center for Nasal Cavity Squamous Cell Carcinoma

Genetic Tests for Nasal Cavity Squamous Cell Carcinoma

Anatomical Context for Nasal Cavity Squamous Cell Carcinoma

MalaCards organs/tissues related to Nasal Cavity Squamous Cell Carcinoma:

39
Lung, Brain, Liver, Skin, Breast, Lymph Node, Kidney

Publications for Nasal Cavity Squamous Cell Carcinoma

Articles related to Nasal Cavity Squamous Cell Carcinoma:

id Title Authors Year
1
[Expression and significance of matrix metalloproteinase and tissue inhibitor of metalloproteinase in nasal cavity squamous cell carcinoma]. ( 21624249 )
2011
2
Nasal cavity squamous cell carcinoma presenting as a nasal sidewall nodule: treatment with Mohs surgery, partial rhinectomy, and adjuvant radiotherapy. ( 16681669 )
2006
3
Cerebral radionecrosis with cystic degeneration following radiotherapy for nasal cavity squamous cell carcinoma: a case report. ( 15253473 )
2004
4
Nasal cavity squamous cell carcinoma in Wegener's granulomatosis. ( 11405874 )
2001

Variations for Nasal Cavity Squamous Cell Carcinoma

Cosmic variations for Nasal Cavity Squamous Cell Carcinoma:

9 (show all 26)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10651 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.530C>G p.P177R 14
2 COSM10656 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.742C>T p.R248W 14
3 COSM43962 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.805A>G p.S269G 14
4 COSM10648 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.524G>A p.R175H 14
5 COSM10650 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.529C>T p.P177S 14
6 COSM10659 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.817C>T p.R273C 14
7 COSM10704 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.844C>T p.R282W 14
8 COSM44097 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.530C>T p.P177L 14
9 COSM43555 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.736A>G p.M246V 14
10 COSM10660 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.818G>A p.R273H 14
11 COSM43881 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.757A>T p.T253S 14
12 COSM44338 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.845G>A p.R282Q 14
13 COSM45046 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.542G>C p.R181P 14
14 COSM10647 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.404G>T p.C135F 14
15 COSM10654 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.637C>T p.R213* 14
16 COSM44312 TP53 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.511G>A p.E171K 14
17 COSM20953 STK11 upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.613G>A p.A205T 14
18 COSM763 PIK3CA upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 14
19 COSM775 PIK3CA upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 14
20 COSM581 NRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.181C>G p.Q61E 14
21 COSM518 KRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.34G>C p.G12R 14
22 COSM522 KRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.35G>C p.G12A 14
23 COSM521 KRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.35G>A p.G12D 14
24 COSM551 KRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 14
25 COSM487 HRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.37G>A p.G13S 14
26 COSM500 HRAS upper aerodigestive tract,sinonasal and nasal cavity,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 14

Expression for Nasal Cavity Squamous Cell Carcinoma

Search GEO for disease gene expression data for Nasal Cavity Squamous Cell Carcinoma.

Pathways for Nasal Cavity Squamous Cell Carcinoma

GO Terms for Nasal Cavity Squamous Cell Carcinoma

Cellular components related to Nasal Cavity Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 proteinaceous extracellular matrix GO:0005578 9.46 MMP2 MMP9 TIMP1 TIMP2
2 extracellular matrix GO:0031012 9.26 MMP2 MMP9 TIMP1 TIMP2
3 keratin filament GO:0045095 8.8 KRT5 KRT7 KRT8

Biological processes related to Nasal Cavity Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cornification GO:0070268 9.43 KRT5 KRT7 KRT8
2 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.32 MMP2 MMP9
3 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.16 TIMP1 TIMP2
4 negative regulation of metallopeptidase activity GO:1905049 8.96 TIMP1 TIMP2
5 extracellular matrix disassembly GO:0022617 8.92 MMP2 MMP9 TIMP1 TIMP2

Molecular functions related to Nasal Cavity Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metalloendopeptidase inhibitor activity GO:0008191 8.62 TIMP1 TIMP2

Sources for Nasal Cavity Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....